Therapy List

Emerging Therapy Solutions (ETS) Current General Therapies Services List

Updated: March 24, 2021

Emerging Therapy Solutions® provides access to contracted hospitals or facilities that offer condition-specific evaluations necessary to determine the appropriate procedures and therapies, and the associated services and supplies, that are required for the treatment of complex conditions.

Below is a general ETS therapies services list of the US Food and Drug Administration (FDA) approved cell and gene therapies with conditions pertinent to those therapies, along with transplant and implant services.

NOTE: This list is subject to change with the availability of new therapies and medical innovations.

Service Type (Listed by Therapy Name)

Chimeric Antigen Receptor (CAR) T-cell Therapies

Breyanzi® (lisocabtagene maraleucel)1
For relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma, and follicular lymphoma grade 3B

Kymriah® (tisagenlecleucel)2
For relapsed or refractory acute lymphoblastic leukemia up to age 25, and for adult relapsed or refractory diffuse large B-cell lymphoma

Tecartus™ (brexucabtagene autoleucel)3
For relapsed or refractory mantle cell lymphoma

Yescarta® (axicabtagene ciloleucel)4
For relapsed or refractory B-cell non-Hodgkin’s lymphoma

Gene Therapies

Luxturna® (voretigene neparvovec)5
For biallelic RPE65 gene mutation

Zolgensma® (onasemnogene abeparvovec-xioi)6
For spinal muscular atrophy

Transplants and Implants

Kidney Transplant

Pancreas Transplant

Auto Islet Cell Infusion

Liver Transplant

Small Bowel Transplant

Heart Transplant

Lung or Double Lung Transplant

Mechanical Circulatory Support (VAD†, Total Heart) Implant

Autologous (HCT‡) Transplant

Allogeneic (Related or Unrelated HCT) Transplant

Other Transplant

*This list only contains cell and gene therapies which may be eligible for coverage. To be covered, any therapy must meet all the other terms and conditions applicable to coverage. This list may be modified at any time by adding or deleting cell or gene therapies or other services. Any such modifications will be made by updating this website page. The version of this list available on any given date is applicable to therapies which may be provided on that date.

We are ready to help you manage your risk.

Contact Us